MYND — MYND Life Sciences Share Price
Last trade - 00:00- CA$3.35m
- CA$6.35m
- 18
- 37
- 81
- 42
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Oct | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
MYND Life Sciences Inc. is a Canada-based life science based, neuro-pharmaceutical drug development company. The Company is working on advancing medicines based on neuro-anti-inflammatory substances through rigorous science and clinical trials, with an initial focus on major depressive disorder (MDD). Its lead development program, referred to as the human mycogene modulation program (HMM), is designed to treat neuropsychiatric disorders through the dosing of formulations of psilocybin and/or its analogs. It is evaluating additional indications for its HMM program, including autoimmune disorders (AD) and other MDD conditions as well as multiple sclerosis, and Alzheimer’s disease. Its programs include MYND-604 and MYND-778.
Directors
- Last Annual
- October 31st, 2023
- Last Interim
- July 31st, 2024
- Incorporated
- November 26th, 2020
- Public Since
- May 26th, 2021
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 47,817,182
- Address
- 105-2248 Elgin Ave, PORT COQUITLAM, V3C 2B2
- Web
- https://myndsciences.com/
- Phone
- +1 7809650122
- Contact
- Luke Warkentin
- Auditors
- Manning Elliott LLP
Upcoming Events for MYND
Similar to MYND
Albert Labs International
Canadian Securities Exchange
Algernon Pharmaceuticals
Canadian Securities Exchange
Asep Medical Holdings
Canadian Securities Exchange
Awakn Life Sciences
Canadian Securities Exchange
BetterLife Pharma
Canadian Securities Exchange
FAQ
As of Today at 22:09 UTC, shares in MYND Life Sciences are trading at CA$0.07. This share price information is delayed by 15 minutes.
Shares in MYND Life Sciences last closed at CA$0.07 and the price had moved by +133.33% over the past 365 days. In terms of relative price strength the MYND Life Sciences share price has outperformed the Toronto Stock Exchange 300 Composite Index by +110.33% over the past year.
There is no consensus recommendation for this security.
Find out moreMYND Life Sciences does not currently pay a dividend.
MYND Life Sciences does not currently pay a dividend.
MYND Life Sciences does not currently pay a dividend.
To buy shares in MYND Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.07, shares in MYND Life Sciences had a market capitalisation of CA$3.35m.
Here are the trading details for MYND Life Sciences:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: MYND
Based on an overall assessment of its quality, value and momentum MYND Life Sciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MYND Life Sciences. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +186.14%.
As of the last closing price of CA$0.07, shares in MYND Life Sciences were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The MYND Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on MYND Life Sciences' directors